Monica Radu

Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial

Ira M. Jacobson, Gregory J. Dore, Graham R. Foster et al. · The Lancet · 2014 · 436 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +16

Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial

Heiner Wedemeyer, Cihan Yurdaydın, Svenja Hardtke et al. · The Lancet Infectious Diseases · 2019 · 193 citations

Pharmacy, Pharmacology, Pharmacotherapy +14

Residual low HDV viraemia is associated HDV RNA relapse after PEG‐IFNa‐based antiviral treatment of hepatitis delta: Results from the HIDIT‐II study

Birgit Bremer, Olympia E. Anastasiou, Svenja Hardtke et al. · Liver International · 2020 · 26 citations · Full text

Pharmacy, Infectious Diseases, Molecular Biology +16

Use of quantitative serum HBsAg for optimization of therapy in chronic hepatitis B patients treated with pegylated interferon alfa-2a: a Romanian cohort study.

Valeriu Gheorghiţă, Florin Alexandru Căruntu, Manuela Curescu et al. · PubMed · 2013 · 15 citations

Pharmacy, Pharmacology, Pharmacotherapy +17

Sa2072 Simeprevir (TMC435) With Peginterferon/Ribavirin for Chronic HCV Genotype-1 Infection in Treatment-Nai;auve Patients: Results From QUEST-1, a Phase III Trial

Ira M. Jacobson, Gregory J. Dore, Graham R. Foster et al. · Gastroenterology · 2013 · 14 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17